Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Cytovant is a biopharmaceutical company focused on developing novel and innovative cellular therapeutics.
Bionetix Therapeutics is a developer of anticancer drugs designed for cancer treatment.
Adapt is a brand and content marketing platform that focuses on D2C concept, customer feedback and constant analysis.
Vllo is a video editing application.
Muzlive is a new integrated platform for the global music market.
Dr.Kitchen is a professional research company focusing on diet food for diabetics.
WAGTI provides marketing solutions to sports federations or leagues.
Social Network is a specialist platform that serves korean trends.
Art Community for Emerging Artists, Critics, Art Agencies and Art Lovers around the World
Yello Digital Marketing is a total media platform.
US Alliance is a collaboration on investment activities.
General Bio developing new bio materials from microorganisms and natural and functional ingredients.
SMATOOS JAPAN is a global educational technology company that designs applications to promote innovation and learning in children.
Mirae Asset Venture Investment has invested in 109 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Mirae Asset Venture Investment's top investment sectors include Biotechnology, Therapeutics, Health Care, Brand Marketing, Content. The firm invests across 35 different industry categories.
Among tracked funding rounds, Cytovant received $23.5M in a Series Unknown round. Mirae Asset Venture Investment's total known invested capital is $1.0B.
Mirae Asset Venture Investment's average investment size is $12.5M across its portfolio of 109 companies.
Recent Mirae Asset Venture Investment portfolio additions include Cytovant, Bionetix Therapeutics. These companies were founded in 2020 or later.